Evergreen edition presents information on the immunizing agents available in Canada and their use in the prevention of communicable diseases.
Le présent Guide (édition évolutive) contient des renseignements sur les agents immunisants disponibles au Canada et sur leur utilisation en vue de prévenir les maladies transmissibles.
Use of Measles-Mumps-Rubella (MMR) Vaccine for the Management of Mumps Outbreaks in Canada: An Advisory Committee Statement
Utilisation du vaccin contre la rougeole, la rubéole et les oreillons (RRO) pour la prise en charge des éclosions d’oreillons au Canada : Déclaration d'un comité consultatif
There is no scientific evidence that MMR vaccine causes autism. The question about a possible link between MMR vaccine and autism has been extensively reviewed by independent groups of experts in the United States, including the National Academy of Sciences’ Institute of Medicine (now renamed the National Academy of Medicine). These reviews have concluded that the available epidemiologic evidence does not support a causal link between MMR vaccine and autism
The 2016 mid-term review of the Global Measles-Rubella Strategic Plan 2012–20 for achieving measles-rubella elimination concluded that the full potential of strategies and activities to strengthen routine immunization (RI) service delivery had not been met. In December 2017, researchers contacted the World Health Organization (WHO) and partner agency immunization staff in all six WHO Regions who identified 23 countries working on measles or rubella elimination that have implemented examples of recommended activities to improve RI, adapted to their needs.
A solid majority of Americans believe vaccinating their children against measles, mumps and rubella has high preventive health benefits. But several groups – particularly parents of young children – are less convinced of the benefits and more concerned about the safety of the MMR vaccine.
During 2000-2016, rubella-containing vaccine was introduced in 53 countries, including 20 introductions after 2012. By December 2016, 152 (78%) of 194 countries were using the vaccine. These introductions and increased rubella vaccine coverage globally resulted in a decrease in reported rubella cases from 670,894 cases in 2000, to 94,277 cases in 2012, to 22,361 cases in 2016. Elimination of rubella and congenital rubella syndrome was verified in the WHO Region of the Americas in 2015, and 33 (62%) of 53 countries in the European Region have now eliminated endemic rubella and congenital rubella syndrome.
Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008–2011
This study was undertaken to estimate rubella susceptibility in a cohort of pregnant women in Canada and to identify associated socioeconomic and demographic factors.
Emphasizes that while vaccination programs have eliminated or significantly reduced many vaccine-preventable diseases, these diseases still exist and can once again become common and deadly if vaccination coverage does not continue at high levels.